Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants

Summary

The primary objective of this study is to demonstrate the safety and efficacy of cellular immunotherapy with MDR-103 for induction of functional immune tolerance in past recipients of human leukocyte antigen (HLA)-matched, living donor kidney transplants.

Timeline

Start

2024-12

Primary completion

2025-08

Completion

2025-10

Outcome

Outcome not reported

Stopped (Business): “Lack of funding”

Drugs

Indications